SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
KaloBios Pharmaceuticals, Inc. Initiates Phase 2 Study With KB001-A Humaneered® Monoclonal Antibody in Cystic Fibrosis Patients